Cliff Asness’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.09M Sell
9,541
-6,410
-40% -$551K ﹤0.01% 2957
2026
Q1
$1.33M Buy
15,951
+6,612
+71% +$524K ﹤0.01% 2621
2025
Q4
$727K Buy
9,339
+719
+8% +$48.6K ﹤0.01% 2720
2025
Q3
$488K Buy
8,620
+537
+7% +$24.2K ﹤0.01% 2825
2025
Q2
$353K Buy
+8,083
New +$278K ﹤0.01% 2780
2025
Q1
Sell
-6,576
Closed -$265K 3173
2024
Q4
$265K Sell
6,576
-5,684
-46% -$257K ﹤0.01% 2558
2024
Q3
$580K Buy
+12,260
New +$541K ﹤0.01% 2101

Other funds holding KYMR

Cliff Asness's KYMR Position: Q2 2026 in Review

Cliff Asness reduced its Kymera Therapeutics (KYMR) stake by 40% in Q2 2026, selling an estimated $551K and leaving 9,541 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2957.

Cliff Asness first reported a position in KYMR in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.33M in Q1 2026. 273 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Cliff Asness held 9,541 shares of Kymera Therapeutics worth $1.09M as of Q2 2026.
  • Cliff Asness sold 6,410 Kymera Therapeutics shares in Q2 2026, an estimated $551K.
  • Kymera Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2957 holding.
  • Cliff Asness first reported a position in Kymera Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Cliff Asness's Kymera Therapeutics position peaked at $1.33M in Q1 2026.
  • 273 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.